<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Supportive care for locally advanced or metastatic exocrine pancreatic cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Supportive care for locally advanced or metastatic exocrine pancreatic cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Supportive care for locally advanced or metastatic exocrine pancreatic cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlos Fernandez-del Castillo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramon E Jimenez, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet E Murphy, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A majority of patients with exocrine pancreatic cancer are diagnosed with adenocarcinomas arising from the ductal epithelium. (See  <a class="medical medical_review" href="/d/html/2510.html" rel="external">"Pathology of exocrine pancreatic neoplasms"</a>.)</p><p>Most patients with exocrine pancreatic cancer present with advanced disease, due to its aggressive natural history. Surgical resection offers the only chance of cure. However, only 15 to 20 percent of patients have resectable disease at initial diagnosis; the majority have either locally advanced or metastatic disease. Most also suffer from a significant symptom burden, and they frequently require symptom management [<a href="#rid1">1</a>]. Typical patients will require numerous interventions targeting pain, anorexia and weight loss, depression and anxiety, biliary obstruction, gastric outlet obstruction, ascites, and venous thromboembolism.</p><p>This topic review will summarize supportive care for symptoms related to locally advanced or metastatic exocrine pancreatic cancer. The management of patients with pancreatic cancer is presented separately. (See  <a class="medical medical_review" href="/d/html/2482.html" rel="external">"Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis"</a> and  <a class="medical medical_review" href="/d/html/2477.html" rel="external">"Treatment for potentially resectable exocrine pancreatic cancer"</a> and  <a class="medical medical_review" href="/d/html/2479.html" rel="external">"Initial chemotherapy and radiation for nonmetastatic, locally advanced, unresectable and borderline resectable, exocrine pancreatic cancer"</a> and  <a class="medical medical_review" href="/d/html/2475.html" rel="external">"Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"</a>.) </p><p class="headingAnchor" id="H970227417"><span class="h1">IMPORTANCE OF PALLIATIVE CARE</span><span class="headingEndMark"> — </span>All patients with newly diagnosed pancreatic cancer should have a full assessment of symptom burden, psychological status, and social supports as early as possible [<a href="#rid2">2-5</a>]. Many patients with locally advanced or metastatic disease will benefit from formal palliative care consultation and services. Early referral and initiation of palliative care services improve clinical and quality of care outcomes.</p><p>Palliative care is an interdisciplinary specialty that is focused on preventing and relieving suffering, and supporting the best possible quality of life for patients and their families facing serious illness, such as pancreatic cancer. Clinicians who are specialty trained in palliative care provide in-depth pain and symptom management, communication regarding goals of care, and coordinated care across settings and over time. Palliative care aims to relieve suffering in all stages of disease and can be provided at the same time as curative or life-prolonging treatments  (<a class="graphic graphic_figure graphicRef64252" href="/d/graphic/64252.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care", section on 'Palliative care services'</a>.)</p><p>When initiated early in the disease course, palliative care has been shown to improve clinical, quality of care, and survival outcomes. Furthermore, multiple studies have shown that palliative care services improve patients' symptoms, allow patients to avoid hospitalization and to remain safely and adequately cared for at home, lead to better patient and family satisfaction, and significantly reduce prolonged grief and posttraumatic stress disorder among bereaved family members. Palliative care also lowers costs and reduces rates of unnecessary hospitalizations, diagnostic and treatment interventions, and nonbeneficial intensive care when patients are near the end of life. (See  <a class="medical medical_review" href="/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care", section on 'Rationale for palliative care'</a>.)</p><p>The impact of palliative care on reducing aggressiveness of end of life care in patients with advanced pancreatic cancer was shown in a retrospective population-based cohort study of administrative data on 5381 patients diagnosed between 2005 and 2010 in Ontario, Canada [<a href="#rid6">6</a>]. Measures of aggressive end of life care included chemotherapy within 14 days of death and at least one intensive care unit (ICU) admission, more than one emergency department (ED) visit, and more than one hospitalization within 30 days of death. Of the 5381 patients (median survival 75 days), 2816 (52 percent) had received a palliative care consultation. Palliative care consultation was associated with a significant reduction in use of chemotherapy near death (odds ratio [OR] 0.34, 95% CI 0.25-0.46) and a significantly lower risk of ICU admission (OR 0.12, 95% CI 0.08-0.18), multiple ED visits (OR 0.19, 95% CI 0.16-0.23), and multiple hospitalizations near death (OR 0.24, 95% CI 0.19-0.31).</p><p class="headingAnchor" id="H970227448"><span class="h1">MANAGEMENT OF SPECIFIC SYMPTOMS</span><span class="headingEndMark"> — </span>All patients with locally advanced and metastatic pancreatic cancer should be offered aggressive treatment of pain and other symptoms related to the cancer, and/or cancer-directed therapy [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H3607283049"><span class="h2">Pain</span><span class="headingEndMark"> — </span>Pain can be a significant feature of advanced pancreatic cancer, and all patients should have the level of pain and degree of pain relief from analgesics addressed at every clinic visit. Pain is often the major presenting symptom of the disease. Patients describe a gnawing midepigastric pain, which radiates bilaterally under the ribs and into the mid-back, owing to the proximity of pancreatic tumors to the celiac plexus. </p><p class="headingAnchor" id="H2558578035"><span class="h3">Analgesics</span><span class="headingEndMark"> — </span>The mainstay of pain management is typically opioid medication, and palliation of pain can often be successfully achieved by opioid analgesics alone. For patients with persistent nausea and vomiting, for whom taking oral medications is difficult, pain control may be achieved using transdermal patches, provided they have sufficient adipose tissue for transdermal absorption. Because of the proximity of the tumor to the celiac plexus, the pain may be neuropathic in nature, warranting consideration of adjuvant medications such as <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, or <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>. (See  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a> and  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'</a>.)</p><p class="headingAnchor" id="H894173325"><span class="h3">Sympathetic neurolytic blocks</span><span class="headingEndMark"> — </span>Pain can also be managed with local procedures targeting the celiac plexus or splanchnic nerves. Many studies have demonstrated the efficacy of both techniques for pain from pancreatic cancer [<a href="#rid7">7-23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac plexus neurolysis</strong> - The celiac plexus is a dense network of nerves that innervates the upper abdominal organs. It lies anterior to the aorta at the level of the first lumbar vertebra. Pain may be relieved by inhibiting synaptic pathways within the plexus without nerve destruction (ie, celiac plexus block using a bolus injection of local anesthetic) or chemical destruction of the pathways and ganglia using dehydrated (absolute [95%]) alcohol, a procedure termed celiac plexus neurolysis (CPN).</p><p></p><p class="bulletIndent1">CPN can be performed percutaneously, surgically, or under endosonographic guidance. In the past, it has been most commonly performed intraoperatively or percutaneously with fluoroscopic or computed tomographic (CT) guidance. More recent experience has demonstrated that it can also be safely performed during endoscopic ultrasonography (EUS). (See  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p></p><p class="bulletIndent1">CPN appears to be more effective than pharmacologic therapy alone, both for immediate and long-term relief of pain, with reported success rates (typically defined as "less pain") ranging from 50 to 80 percent in multiple studies [<a href="#rid7">7-12</a>]. In one randomized trial, early referral for CPN provided better pain control; less opioid consumption; fewer opioid-related complications, such as constipation and sedation; and a better quality of life as compared with waiting until after failure to obtain pain relief with strong opioids [<a href="#rid13">13</a>]. The EUS approach to CPN, as well as indications for CPN, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5659.html" rel="external">"Endoscopic ultrasound-guided celiac plexus interventions for pain related to pancreatic disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splanchnic nerve block</strong> – The paired splanchnic nerves contain the sympathetic fibers that originate from T5 to L2 and coalesce in the celiac plexus; they pierce the crura of the diaphragm at the T11 and T12 levels prior to joining the celiac ganglion. Chemical splanchnicectomy can be accomplished intraoperatively [<a href="#rid14">14,20</a>], or through percutaneous ultrasound or CT-guided placement of a neurolytic solution (typically absolute [95%] alcohol) posterior to the aorta over the anterolateral surface of the 12<sup>th</sup> thoracic vertebra.</p><p></p><p class="bulletIndent1">The best data on the efficacy of splanchnic nerve neurolysis come from a contemporary randomized trial in which 96 patients with unresectable stage III or IV pancreatic cancer presenting with moderate to severe cancer-related pain were randomly assigned to splanchnic nerve block versus <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> injection placebo control; management of systemic analgesic therapy in both groups used a protocol common to all centers [<a href="#rid19">19</a>]. The primary outcome was pain relief, as measured with a visual analogue scale (VAS) from 1 to 10.</p><p></p><p class="bulletIndent1">Pain relief was greatest with neurolysis for the first three months (largest at the first month, but the effect size was small, mean difference in VAS 0.7 [95% CI 0.3-1.0]), and opioid consumption was also lower in this group for the first five months (largest difference at one month, mean difference in oral <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> milligram equivalents, 95.8 [95% CI 67.4 to 124.1]). No differences in quality of life were observed, but patients undergoing neurolysis had a significantly lower survival rate that appeared limited to those with stage IV disease. This is discussed further below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is either approach superior?</strong> – Although limited, the available data suggest that both procedures are comparable in terms of pain relief, which typically lasts for up to three months [<a href="#rid14">14,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is survival adversely impacted?</strong> – Although many studies have shown that sympathetic neurolysis can improve pain and slow opioid dose escalation, its impact on survival remains controversial. While several studies that have examined this end point suggest that CPN neither improves nor decreases survival [<a href="#rid8">8,23</a>], while others suggest that patients who received early neurolysis for locally unresectable pancreatic cancer had longer survival times compared with other forms of therapy [<a href="#rid20">20,22</a>]. Notably, almost all of these reports included patients with locally advanced unresectable nonmetastatic tumors.</p><p></p><p class="bulletIndent1">However, concerns about inferior survival have been raised in at least two other reports:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a single center retrospective case-control study of 417 patients with unresectable pancreatic cancer who underwent CPN and were compared with 840 control patients with unresectable pancreatic cancer who did not undergo CPN, CPN was negatively associated with survival (median 193 versus 246 days, HR 1.32, 95% CI 1.13-1.54) [<a href="#rid21">21</a>]. This difference persisted in multivariate analysis and was similar in all stage group categories (stage I/II, III, or IV), and whether or not the patient was treated with chemotherapy, radiation, or resection. Approximately 50 percent of the patients in either group had stage IV disease. However, the CPN group had more weight loss (median 20 versus 15 pounds), more opioid use (89 versus 36 percent), and more often had pain at presentation (99 versus 80 percent), all of which could have contributed to poorer performance status in this group independent of CPN.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the randomized trial of splanchnic nerve block versus <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> injection control in 96 patients with unresectable pancreatic cancer described above, overall survival was significantly less in the sympathetic neurolysis group (median survival 102 versus 151 days, HR for death 1.56, 95% CI 1.03-2.35) [<a href="#rid19">19</a>]. This detrimental impact was limited to those with stage IV (HR 1.94, 95% CI 1.29-2.93) but not stage III inoperable disease (HR 1.08, 95% CI 0.59-1.97).</p><p></p><p class="bulletIndent1">In our view, these data are hypothesis generating rather than definitive. The trial was not powered to assess survival as a primary endpoint. Furthermore, one of the eligibility requirements for the trial was patients in palliative care who would not be receiving any anticancer treatments, including radiation therapy, chemotherapy, or targeted therapies. Data were not provided on the differences in anticancer therapy between the two groups. For all of these reasons, we would still offer nerve blocks to patients with either stage III or stage IV disease, although others disagree [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H37086510"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>A short course of palliative radiation therapy (RT) may also significantly alleviate pain due to local invasion of pancreatic cancer. External beam RT with or without concomitant chemotherapy is associated with resolution of cancer-related pain in 35 to 65 percent of patients, frequently with improvement in cachexia and obstructive symptoms [<a href="#rid25">25-27</a>]. However, it may take several weeks to achieve its maximal effect. Because relief from pain is generally faster with sympathetic neurolysis, it is the preferred approach, when feasible.</p><p class="headingAnchor" id="H2"><span class="h2">Jaundice</span><span class="headingEndMark"> — </span>Unrelieved jaundice from an obstructed biliary tree causes pruritus and an increased risk for cholangitis, although cholangitis is less common in native bile ducts than in previously stented bile ducts. Ultrasound, CT, or magnetic resonance cholangiopancreatography (MRCP) are commonly performed in jaundiced patients to distinguish obstructive jaundice from jaundice due to liver failure in patients with underlying liver disease and/or extensive metastatic disease. These studies typically demonstrate dilated intra- and extrahepatic biliary ducts. (See  <a class="medical medical_review" href="/d/html/2501.html" rel="external">"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Jaundice'</a>.)</p><p>Palliation of jaundice is important to maintain liver health, prevent cholangitis, and restore bilirubin levels to a normal range to allow for the administration of cytotoxic chemotherapy. (See  <a class="medical medical_review" href="/d/html/2501.html" rel="external">"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Jaundice'</a>.)</p><p>Options for palliation of jaundice in patients who have obstructive jaundice from locally advanced, unresectable disease are surgical bypass or placement of a stent across the area of biliary tract obstruction. Palliation of obstructive jaundice in patients who are not undergoing an attempt at surgical resection is usually accomplished by the endoscopic or percutaneous placement of an expandable metal stent, while surgical bypass is generally reserved for those in whom stent placement is not possible due to technical reasons and for those found to be unresectable at the time of operative exploration.</p><p class="headingAnchor" id="H3"><span class="h3">Surgical options</span><span class="headingEndMark"> — </span>The surgical options for achieving biliary decompression include an anastomosis between the gallbladder and jejunum (cholecystojejunostomy) or common bile duct and jejunum (choledochojejunostomy) [<a href="#rid28">28-30</a>]. A cholecystojejunostomy should only be considered if the cystic duct enters the common bile duct at a site distant from the tumor. A choledochojejunostomy should only be performed if the common duct is &gt;1 cm in diameter. Drainage is successful in returning the serum bilirubin concentration in approximately 90 percent of patients; in the remainder, persistent hyperbilirubinemia may be seen due to impaired hepatic function [<a href="#rid28">28</a>].</p><p>One advantage of surgical bypass is the ability to perform prophylactic or therapeutic gastrojejunostomy to avoid gastroduodenal obstruction and celiac plexus neurolytic block for pain control (see <a class="local">'Pain'</a> above and <a class="local">'Gastric outlet obstruction'</a> below). However, the risk associated with surgery in these typically debilitated patients is not small. In one report, the postoperative mortality and perioperative morbidity rates were 3.1 and 22 percent, respectively, and the median survival was 6.5 months [<a href="#rid31">31</a>]. As a result, surgical bypass is generally reserved for those in whom stent placement is not possible due to technical reasons, and for those found to be unresectable at the time of operative exploration.</p><p class="headingAnchor" id="H4"><span class="h3">Stents</span><span class="headingEndMark"> — </span>Stents can provide minimally invasive, effective palliation of jaundice [<a href="#rid32">32</a>]. Most jaundiced patients can be successfully managed using stents, and relatively few require surgical biliary-enteric bypass as a planned palliative procedure. Randomized trials and a meta-analysis have shown no difference in survival between endoscopic stent placement and surgical bypass for malignant obstructive jaundice; stented patients have more frequent readmissions for stent occlusion, recurrent jaundice, and cholangitis (below), but lower morbidity and procedure-related mortality [<a href="#rid33">33-37</a>].</p><p class="headingAnchor" id="H718237155"><span class="h4">Plastic versus metal stents</span><span class="headingEndMark"> — </span>A variety of plastic and metal stents, both covered and uncovered, are available for endoscopic deployment. A systematic review and a meta-analysis concluded that, compared with plastic stents, metal stents had a lower risk of recurrent obstruction but were not superior with regard to technical success, therapeutic success, mortality, or complications [<a href="#rid37">37,38</a>]. As a result, the decision to use one versus another should be guided by expected length of survival, quality of life, costs, and physician expertise (see  <a class="medical medical_review" href="/d/html/13925.html" rel="external">"Endoscopic stenting for malignant biliary obstruction", section on 'Types of biliary stents'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The placement of a plastic stent is inexpensive and effective, and the stent can be easily removed or exchanged. Plastic stents, however, eventually develop occlusion by sludge and/or bacterial biofilm, and maintaining biliary drainage with plastic stents usually requires repeated endoscopic retrograde cholangiopancreatographies (ERCPs) since the median duration of patency is approximately three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metal stents extend the duration of stent patency (approximately 8 to 12 versus 2 to 5 months). However, metal stents have significantly higher costs and may not be removable. Thus, the diagnosis of unresectable or metastatic disease must be firmly established before a metal stent is deployed.</p><p></p><p class="bulletIndent1">For patients with unresectable malignant biliary obstruction, self-expanding metal stents appear to be more cost effective than plastic stents, especially for individuals with a short life expectancy who place a high value on avoiding repeated interventions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient's treatment plan may not be known during the initial ERCP (eg, if biliary drainage is required before staging can be completed). Options in this setting include placing a plastic (and thus easily removed) stent or a self-expandable metal stent (which provides longer term patency). A Monte Carlo decision analysis compared several strategies in patients with obstructive jaundice from pancreatic cancer to an undetermined surgical plan, and the results suggested that a short-length self-expanding metal stent is the preferred initial treatment for overall cost minimization [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">In general, the placement of a covered metal stent could be considered in patients with potentially resectable pancreatic cancer, especially if surgery is likely to be delayed (eg, for neoadjuvant chemotherapy, with the prevalence of this approach increasing). However, this is a controversial area, and some surgeons prefer a plastic stent in this setting. It may be helpful to speak with the surgeon prior to stent placement if a patient appears to have a potentially resectable tumor. (See  <a class="medical medical_review" href="/d/html/91408.html" rel="external">"Surgical resection of lesions of the head of the pancreas", section on 'Preoperative biliary drainage'</a> and  <a class="medical medical_review" href="/d/html/2482.html" rel="external">"Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis", section on 'Role of preoperative biliary drainage'</a>.)</p><p></p><p class="bulletIndent1">The 2018 guidelines from the European Society of Gastrointestinal Endoscopy suggest use of a self-expanding metal stent for preoperative drainage for malignant strictures only in the presence of cholangitis, or severe symptomatic jaundice, or a delay in surgery; or prior to neoadjuvant chemotherapy in jaundiced patients [<a href="#rid40">40</a>]. Plastic stents are reserved for those with benign biliary strictures.</p><p></p><p class="headingAnchor" id="H718237106"><span class="h4">Covered versus uncovered stents</span><span class="headingEndMark"> — </span>Several trials have evaluated differences in stent patency rates between covered and uncovered metal stents for the treatment of distal malignant biliary disease; despite showing significantly less tumor ingrowth, patency rates are not higher for covered stents. This can likely be explained by the many other etiologies of stent occlusion other than tumor ingrowth, including tumor overgrowth and stent obstruction by debris and biliary sludge. One potential benefit of the covered metal stents is that they are more easily removable than are uncovered metal stents, but possible disadvantages include a higher incidence of cholecystitis from extrinsic occlusion of the cystic duct and stent migration. As noted above, the use of a metal stent in a patient who is a candidate for resection should be reviewed with the surgeon prior to placement. (See  <a class="medical medical_review" href="/d/html/13925.html" rel="external">"Endoscopic stenting for malignant biliary obstruction", section on 'Metal stents'</a> and  <a class="medical medical_review" href="/d/html/13925.html" rel="external">"Endoscopic stenting for malignant biliary obstruction", section on 'Adverse events'</a>.)</p><p class="headingAnchor" id="H718236285"><span class="h4">Percutaneous versus endoscopically placed stents</span><span class="headingEndMark"> — </span>Endoscopic stenting is generally preferable to percutaneous approaches because of a more favorable adverse event rate, except for in patients in whom endoscopic stent placement has failed or is technically unfeasible because of duodenal obstruction or prior surgical bypass of the bile ducts and ampulla, in which a retrograde approach to the area is not possible [<a href="#rid41">41,42</a>]. However, percutaneous drainage may sometimes be the best approach for patients with advanced hilar metastases from pancreas cancer.</p><p class="headingAnchor" id="H2939542706"><span class="h4">Infectious complications of stent placement</span><span class="headingEndMark"> — </span>Endoscopic and percutaneous internal/external stents are associated with a risk for cholangitis because intubation of the ampulla of Vater introduces intestinal flora into a previously sterile area. In one series of 96 patients followed prospectively over a median 9.6 months (89 percent with a metal stent; the remainder were plastic), 41 (43 percent) developed a stent-related event. The rate of cholangitis was 39 percent, the stent obstruction rate was 29 percent, and simultaneous obstruction/cholangitis developed in 32 percent. Consequences relating to stent-related events included chemotherapy delay (24 percent), discontinuation of therapy (17 percent), and death (22 percent). The median time to stent-related event was 4.4 months (95% CI 3.6-5.5) [<a href="#rid43">43</a>]. Importantly, cholangitis is also a concern for patients for whom draining is incomplete. (See  <a class="medical medical_review" href="/d/html/641.html" rel="external">"Infectious adverse events related to endoscopic retrograde cholangiopancreatography (ERCP)", section on 'Acute cholangitis'</a>.)</p><p class="headingAnchor" id="H3194406648"><span class="h2">Gastric outlet obstruction</span><span class="headingEndMark"> — </span>Approximately 15 to 20 percent of patients with pancreatic cancer will develop duodenal obstruction leading to gastric outlet obstruction, although it is typically not present at diagnosis [<a href="#rid28">28</a>]. Symptoms include early satiety, nausea, postprandial vomiting, and weight loss. Endoscopic duodenal stenting is successful in the majority of cases, and the median duration of stent patency is approximately six months [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H333622367"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>To avoid this complication, many surgeons create a prophylactic palliative gastrojejunostomy at the same time as a biliary bypass in those who are deemed to be unresectable at exploration [<a href="#rid28">28</a>]. The benefit of a prophylactic gastrojejunostomy in this setting was shown in a meta-analysis of three prospective trials comparing prophylactic gastroenterostomy plus biliodigestive anastomosis versus no bypass or a biliodigestive bypass alone [<a href="#rid45">45</a>]. For patients undergoing prophylactic gastroenterostomy, the risk of a gastric outlet obstruction during follow-up was significantly lower (odds ratio 0.06, 95% CI 0.02-0.21), while rates of postoperative morbidity (including delayed gastric emptying) and mortality were not higher. The average duration of hospital stay was three days longer in the group that had prophylactic gastroenterostomy.</p><p>Despite these data, the real benefit of this procedure in patients with unresectable pancreatic cancer has been questioned. An open surgical procedure to treat biliary or gastric obstruction is not needed in the vast majority of patients with unresectable pancreatic cancer who do not undergo initial laparotomy (98 percent in one report [<a href="#rid46">46</a>]). Furthermore, delayed gastric emptying is not infrequent after a prophylactic gastrojejunostomy [<a href="#rid47">47</a>].</p><p>However, when unresectable disease is found at the time of operative exploration, our practice is to routinely perform a posterior retrocolic gastrojejunostomy whenever biliary bypass is performed, regardless of the presence or absence of symptoms of gastric outlet obstruction.</p><p class="headingAnchor" id="H6"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The two main treatment options for gastric outlet obstruction are enteral stenting and surgical bypass, which can often be performed laparoscopically. For many patients who are not undergoing an attempt at surgical resection, particularly those with advanced disease, a poor performance status, and a short life expectancy (eg, two to six months), duodenal stents are a reasonable alternative to surgical gastrojejunostomy, provided that an experienced endoscopist familiar with the technique is available [<a href="#rid48">48</a>]. However, long-term relief of obstruction may be more likely in surgically managed patients. In our view, there are benefits and drawbacks to both approaches, and the decision for endoscopic stent placement versus surgical bypass must be individualized based upon local expertise, as well as disease stage, performance status, comorbidity, and estimated life expectancy.</p><p>For many patients with symptomatic gastric outlet obstruction who are not undergoing an attempt at definitive resection, endoscopically placed expandable metal stents provide good symptom palliation and may be preferred over palliative gastrojejunostomy, particularly for patients with advanced disease and a poor performance status. </p><p>However, there are few studies directly comparing endoscopic stent placement to surgical gastrojejunostomy. One Dutch multicenter trial demonstrated faster initial symptom relief with stent placement but higher rates of major complications, recurrent symptoms, and need for reinvention [<a href="#rid49">49</a>]. Long-term relief was more likely after surgical bypass. This subject is addressed in detail separately. (See  <a class="medical medical_review" href="/d/html/2676.html" rel="external">"Enteral stents for the palliation of malignant gastroduodenal obstruction"</a> and  <a class="medical medical_review" href="/d/html/2621.html" rel="external">"Gastric outlet obstruction in adults", section on 'Malignant obstruction'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Delayed gastric emptying</span><span class="headingEndMark"> — </span>Up to 60 percent of patients with pancreatic cancer have slowed gastric emptying without evidence of gastroduodenal tumor invasion [<a href="#rid50">50</a>]. A possible explanation is tumor infiltration into the nerve plexuses. This invariably leads to anorexia, and in approximately one-third of patients, nausea and vomiting are present, which may be erroneously attributed to gastric or duodenal obstruction. However, a gastrojejunostomy is ineffective in relieving symptoms in such patients. Diagnosis can be made with gastric emptying study or as a diagnosis of exclusion when ruling out mechanical obstruction.</p><p>Unfortunately, anorexia, nausea, and vomiting due to delayed gastric emptying are often difficult to control, although prokinetic agents such as <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> may help [<a href="#rid50">50</a>]. Several nonpharmacologic interventions are available for decompression in patients with persistent vomiting; decompression using a "venting" percutaneous endoscopic gastrostomy (PEG) tube can be more comfortable than a nasogastric tube  (<a class="graphic graphic_table graphicRef76547" href="/d/graphic/76547.html" rel="external">table 1</a>).</p><p>For the newly diagnosed patient who presents with severe symptoms but has not yet undergone chemotherapy, bridge nutrition may be beneficial. Combined venting/feeding tubes (gastrostomy/jejunostomy) can both palliate nausea/vomiting and provide an opportunity for nutritional support during active therapy in patients who have refractory gastroparesis; the postpyloric feeding bypasses the area of dysmotility. For patients who cannot eat because of delayed gastric emptying and who are otherwise candidates for chemotherapy, this is a preferred approach over total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> due to the infectious risks of parenteral nutrition, as well as the missed opportunity of utilizing an otherwise functional intestinal tract. (See  <a class="medical medical_review" href="/d/html/2199.html" rel="external">"Overview of managing common non-pain symptoms in palliative care", section on 'Nausea with or without vomiting'</a> and  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Psychological conditions</span><span class="headingEndMark"> — </span>The diagnosis of cancer is unsettling to any patient, and the knowledge of the aggressive nature of locally advanced and metastatic pancreatic cancer may lead to psychological conditions such as adjustment disorder, depression, and anxiety among others. Patients who are depressed experience a significant worsening of their quality of life and have more intense pain compared with those who are not depressed [<a href="#rid51">51</a>].</p><p>Depression has been reported as the presenting symptom of pancreatic cancer in a significant proportion of new cases. A systemic review of 71 studies found that depressive symptoms were a prodrome in approximately 38 to 45 percent of patients newly diagnosed with pancreatic cancer, while prodromal anxiety was observed in approximately 12 percent [<a href="#rid52">52,53</a>]. The characteristic presentation is the older patient with minimal clinical findings presenting with "loss of ambition," "loss of push," "lack of go," and a kind of premonition or foreboding of having cancer [<a href="#rid54">54</a>].</p><p>All patients can benefit from a discussion of their psychosocial concerns and their available support systems [<a href="#rid3">3,4</a>]. Some patients may benefit from cancer support groups, which can be found through the American Cancer Society and other cancer organizations. Others may warrant treatment with antidepressants or anxiolytics, and others may need referral for ongoing formal support from a social worker or psychiatrist. (See  <a class="medical medical_review" href="/d/html/4853.html" rel="external">"Management of psychiatric disorders in patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/2205.html" rel="external">"Assessment and management of depression in palliative care"</a> and  <a class="medical medical_review" href="/d/html/83708.html" rel="external">"Overview of anxiety in palliative care"</a>.)</p><p class="headingAnchor" id="H120656182"><span class="h2">Venous thromboembolism</span></p><p class="headingAnchor" id="H1801337917"><span class="h3">Risk of VTE in pancreatic cancer</span><span class="headingEndMark"> — </span>Pancreatic cancer is associated with a high risk for venous thromboembolism (VTE). This includes deep venous thrombosis (DVT), pulmonary embolism, visceral vein thrombi portal vein, or superior mesenteric vein thrombus. In patients with pancreatic cancer, the incidence of VTE is four to seven times higher than those with other adenocarcinomas [<a href="#rid55">55,56</a>]. The risk of VTE is highest in the first three months after diagnosis, and chemotherapy further increases the risk [<a href="#rid57">57-61</a>]. Patients with VTE (especially splanchnic venous thrombosis) are at high risk for recurrent VTE as well as worsened overall survival [<a href="#rid55">55,58,62-64</a>]. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p>All patients should be educated as to the warning signs and symptoms of VTE [<a href="#rid65">65</a>]. Physical examination of the legs for asymmetric pitting edema, erythema, and warmth is a crucial part of each office visit, and the threshold to perform a CT angiogram in the setting of tachycardia or pleuritic chest pain should be extremely low. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a> and  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p class="headingAnchor" id="H120656703"><span class="h3">Prophylaxis</span></p><p class="headingAnchor" id="H3355523609"><span class="h4">Ambulatory patients</span><span class="headingEndMark"> — </span>For most ambulatory patients with pancreatic cancer and no other risk factors for VTE, we do not routinely offer VTE prophylaxis, as this approach has failed to confer an overall survival benefit in randomized trials. </p><p>However, VTE prophylaxis is an option for select patients with high-risk features for VTE or for those without high-risk features who place a high value on avoiding VTE and are informed on the risks of anticoagulation. High-risk features for VTE in patients with cancer are discussed separately. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Whom to anticoagulate'</a>.)</p><p>When prophylactic anticoagulation is used, options include low molecular weight (LMW) heparin or a direct oral anticoagulant (DOAC), such as <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, or <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>. These agents should be administered at prophylactic doses. Patients should be informed that their baseline bleeding risk may be higher than that for the general population  (<a class="graphic graphic_table graphicRef97160" href="/d/graphic/97160.html" rel="external">table 2</a>). <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is generally not used for prophylactic anticoagulation in cancer patients. Additionally, some patients with pancreatic cancer-associated hypercoagulable states may be relatively resistant to warfarin. Further details on selection of anticoagulant and dosing are discussed separately. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Choice of agent and dose'</a>.)</p><p>Routine anticoagulation for primary VTE prevention is not used in most ambulatory patients with pancreatic cancer, despite the high risk of VTE in this population. In randomized trials, prophylactic anticoagulation reduces VTE risk (although this risk is generally lower in outpatients than in inpatients) but has failed to improve overall survival. Anticoagulation also carries a risk of bleeding. Therefore, the decision to use prophylactic anticoagulation is individualized according to the specific thrombotic and bleeding risks of the patient, along with the relative values placed on avoiding thrombosis versus avoiding bleeding. Other considerations include the associated risks and burdens of continuing anticoagulation when the optimal duration is not well established  (<a class="graphic graphic_table graphicRef120158" href="/d/graphic/120158.html" rel="external">table 3</a>). </p><p>Data for prophylactic anticoagulation in patients with pancreatic cancer are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low molecular weight heparin</strong> – In separate randomized trials of ambulatory patients with advanced pancreatic cancer, prophylactic LMW heparin reduced the risk of symptomatic VTE compared with observation alone (12 versus 28 percent [<a href="#rid58">58</a>]; 5 versus 22 percent [<a href="#rid66">66</a>]; 6 versus 15 percent [<a href="#rid67">67</a>]), with a similar incidence of severe hemorrhage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apixaban</strong><strong> and </strong><strong>rivaroxaban</strong> – In two placebo-controlled randomized trials (AVERT and CASSINI) of ambulatory cancer patients with a Khorana score of two or higher  (<a class="graphic graphic_table graphicRef73002" href="/d/graphic/73002.html" rel="external">table 4</a>), prophylactic anticoagulation with either <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> or <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> reduced the risk of VTE, with an overall low incidence of major bleeding [<a href="#rid68">68,69</a>]. The proportion of patients with pancreatic cancer in the AVERT and CASSINI trials were approximately 15 and 32 percent, respectively. Full results of these studies are discussed separately. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Evidence from clinical trials'</a>.)</p><p></p><p class="bulletIndent1">In a subgroup analysis of 273 patients with pancreatic cancer enrolled in the CASSINI trial, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> had similar rates of asymptomatic or symptomatic DVT, pulmonary embolism, or any death related to DVT relative to placebo up to 180 days (10 versus 13 percent, HR 0.70, 95% CI 0.34-1.43) but had lower rates during the intervention period (10 versus 4 percent, HR 0.35, 95% CI 0.13-0.97) [<a href="#rid70">70</a>]. The risk of major bleeding was similar between in the treatment arms (1.5 versus 2.3 percent). No data were reported on overall survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials have also not demonstrated an overall survival benefit with prophylactic anticoagulation. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Effects on survival'</a>.)</p><p></p><p class="headingAnchor" id="H1778987326"><span class="h4">Hospitalized patients</span><span class="headingEndMark"> — </span>In contrast to ambulatory patients, prophylactic anticoagulation is appropriate for patients with active pancreatic cancer who are hospitalized or who are undergoing major surgery. Routine pharmacologic thromboprophylaxis should not be offered to patients who are admitted for the sole purpose of minor procedures or chemotherapy infusion [<a href="#rid65">65</a>]. This subject is addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Surgical patients'</a> and  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Hospitalized medical patients'</a>.)</p><p class="headingAnchor" id="H1002250223"><span class="h5">Choice of agent</span><span class="headingEndMark"> — </span>Commonly used parenteral agents for VTE prophylaxis in hospitalized patients with cancer include LMW heparin, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, and <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>; the choice among these agents depends on patient-specific factors. Doses of these agents are shown in the table  (<a class="graphic graphic_table graphicRef119688" href="/d/graphic/119688.html" rel="external">table 5</a>). In randomized trials, pharmacologic prophylaxis with LMW heparin, unfractionated heparin, or fondaparinux has been shown to be superior to placebo or mechanical devices in preventing VTE [<a href="#rid71">71-82</a>]. Among these, we prefer LMW heparin because meta-analyses suggest it is superior to unfractionated heparin (twice-daily or three-times-daily dosing regimens), particularly in hospitalized high-risk populations. (See  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Efficacy'</a>.)</p><p>We generally do not use DOACs (eg, direct thrombin inhibitors or direct factor Xa inhibitors) for prophylaxis in surgical patients with pancreatic cancer. While there are current efforts evaluating the use and the efficacy and safety of the factor Xa inhibitors <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, there are no data comparing the risks and benefits of these drugs versus heparins specifically in hospitalized patients with pancreatic cancer. This recommendation is consistent with the American Society of Clinical Oncology (ASCO) guidelines [<a href="#rid65">65</a>]. This subject is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Overview of approach to prevention'</a>.) </p><p><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> generally is not used as prophylactic anticoagulation of relatively brief duration (ie, days to a few weeks) in individuals with cancer due to its delayed onset of antithrombotic action along with its requirement for dose adjustment based on INR monitoring. Although the efficacy of LMW heparin is greater than warfarin for treatment of cancer-associated VTE, its benefit over warfarin has not been demonstrated in the prophylactic setting. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.) </p><p class="headingAnchor" id="H120656759"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Evaluation of the patient with a suspected DVT or pulmonary embolism is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a> and  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and  <a class="medical medical_review" href="/d/html/8195.html" rel="external">"Catheter-related upper extremity venous thrombosis in adults", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a> and  <a class="medical medical_review" href="/d/html/131420.html" rel="external">"Clinical features, diagnosis, and classification of thoracic central venous obstruction"</a>.)</p><p>The standard approach to treatment of a documented VTE (symptomatic or incidentally found) in a patient with pancreatic cancer is early initiation of anticoagulation. The decision to anticoagulate a patient with pancreatic cancer, VTE, and a limited life expectancy can be difficult because of the need for close laboratory monitoring (if <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> is used) as well as the risks of recurrent VTE, bleeding, and death. In addition, as noted above, warfarin has significant drug interactions with the commonly used chemotherapeutic agent <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, and coadministration is contraindicated (see the <a class="external" href="/drug-interactions">drug interactions tool</a>). There are a number of theoretical reasons why heparin-containing products might be more effective than warfarin for this complication, which may or may not be associated with the anticoagulant properties of the heparins [<a href="#rid83">83,84</a>]. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p>A 2008 Cochrane review of six randomized controlled trials in cancer patients receiving long-term treatment for VTE concluded that use of LMW heparin was associated with a statistically significant reduction in subsequent VTE, no statistically significant survival benefit when compared with vitamin K antagonists, and no significant difference in bleeding outcomes [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Principles of therapy'</a>.)</p><p>In addition, accumulating data support the similar efficacy and safety of DOACs compared to LMW heparin. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Principles of therapy'</a>.)</p><p>Recommendations for treatment of VTE in patients with malignancy are available from ASCO, the National Comprehensive Cancer Network (NCCN) [<a href="#rid86">86</a>], the International Society of Thrombosis and Hemostasis (ISTH; updated in 2022), and the American College of Chest Physicians (ACCP; 2021) [<a href="#rid65">65,87-89</a>]. Our suggested approach largely follows updated ASCO and ISTH guidelines [<a href="#rid65">65,89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with VTE (symptomatic or incidental) in the setting of pancreatic cancer who do not have contraindications to anticoagulant use and have a reasonable quality of life and life expectancy, initial anticoagulation may involve LMW heparin, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>, or a DOAC (eg, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>). (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p></p><p class="bulletIndent1">If parenteral treatment is chosen, LMW heparin is generally preferred over <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, even for the initial 5 to 10 days of anticoagulation, if the patient does not have severe renal impairment (defined as creatinine clearance &lt;30 mL/min). (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent1">The management of patients with isolated subsegmental pulmonary embolus, or splanchnic or visceral vein thrombi diagnosed incidentally should be considered on a case-by-case basis, considering the presence or absence of symptoms and the potential benefits and risks of anticoagulation. (See  <a class="medical medical_review" href="/d/html/88016.html" rel="external">"Epidemiology and pathogenesis of portal vein thrombosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation should be avoided if there is active major serious and/or life-threatening bleeding, severe platelet dysfunction or inherited bleeding disorder, platelet count &lt;20,000/microL, or severe uncompensated coagulopathy or in patients undergoing surgery or invasive procedure, such as lumbar puncture, spinal anesthesia, or epidural catheter placement [<a href="#rid87">87</a>]. Relative contraindications include active peptic or other ulceration at high risk of bleeding, active but not life-threatening bleeding (eg, hematuria), intracranial or central nervous system bleeding in the past four weeks, major surgery or serious bleeding in the preceding two weeks, and persistent thrombocytopenia (&lt;50,000/microL). For patients with brain metastases from pancreatic cancer without evidence of intracranial hemorrhage and established VTE, anticoagulation should be offered, although uncertainties remain as to the optimal choice of agent and selection of patients most likely to benefit.</p><p></p><p class="bulletIndent1">When anticoagulation is absolutely contraindicated in the acute treatment setting (diagnosed within four weeks), one treatment option is insertion of an inferior vena cava (IVC) filter if the thrombus burden is considered life threatening. However, based on uncertain short-term benefit and evidence for long-term harm, the insertion of an IVC filter should not be offered to patients with established or chronic thrombosis (diagnosis &gt;4 weeks prior) nor to those with temporary contraindications to anticoagulation therapy (eg, surgery). (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinolytic (thrombolytic) therapy or catheter/surgical embolectomy may be indicated for patients with acute pulmonary embolism and hemodynamic instability or for those with massive iliofemoral or proximal femoral DVT with a high risk of limb gangrene, although the risk and benefit of these invasive measures should be carefully weighed in this population of patients who have a very limited life expectancy. The role of thrombolytic therapy and embolectomy in these settings is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Embolectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For long-term anticoagulation, LMW heparin, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, or <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> for at least six months is preferred because of better efficacy over vitamin K antagonists. However, for patients who do not have Trousseau's syndrome, vitamin K antagonists are an acceptable alternative for long-term therapy if LMW heparin or a DOAC is not available. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Follow-up'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlike standard practice in patients without cancer presenting with unprovoked DVT, the decision to continue anticoagulation beyond the usual three or six months must be balanced against the risk of bleeding, cost of therapy, quality of life, life expectancy, and patient preference. However, because the risk of recurrent VTE is unacceptably high in patients with active pancreatic cancer who stop anticoagulant therapy, we suggest extended (ie, lifelong) anticoagulant therapy for most patients with pancreatic cancer who have VTE. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Duration of anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with recurrent VTE despite standard doses of anticoagulant therapy should be assessed for treatment compliance, heparin-induced thrombocytopenia, or any evidence of mechanical compression related to the malignancy. Checking a Factor Xa level four hours after a dose of LMW heparin provides an accurate indication of therapeutic levels of anticoagulation. While initial dosing should be weight-based, clot burden may impact the dose required to achieve therapeutic anticoagulation. In the setting of true LMW heparin failure, management options include treatment with an alternative anticoagulant regimen, increasing the dose of the LMW heparin [<a href="#rid90">90</a>], or adding an IVC filter to the LMW heparin (although this is not our preferred approach). (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Management of recurrence'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Anorexia, cachexia, and weight loss</span><span class="headingEndMark"> — </span>Anorexia (loss of appetite or reduced caloric intake) and cachexia (an accelerated loss of skeletal muscle in the context of a chronic inflammatory response) is common among patients with pancreatic cancer. (See  <a class="medical medical_review" href="/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Definitions'</a>.)</p><p>Cancer-related cachexia occurs in up to 80 percent of patients with pancreatic cancer, particularly those with metastatic disease. Contributing factors include inappropriately accelerated resting energy expenditure; anorexia and poor oral intake; alterations in nutrient metabolism (eg, increased protein breakdown); and altered pancreatic exocrine function [<a href="#rid91">91</a>], among others. (See  <a class="medical medical_review" href="/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p>All patients with locally advanced or metastatic pancreatic cancer should consult with a nutritionist and/or dietician, if this service is available. Dietary intake should be assessed along with the possible need for dietary supplements. (See  <a class="medical medical_review" href="/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'General dietary principles'</a>.)</p><p>Some patients develop exocrine pancreatic insufficiency and require pancreatic enzyme replacement, which can help improve digestion and absorption of nutrients. (See <a class="local">'Pancreatic exocrine insufficiency'</a> below.)</p><p>Additional pharmacologic management of cancer-associated cachexia syndrome is discussed separately. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia"</a> and  <a class="medical medical_review" href="/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H371010769"><span class="h3">Pancreatic exocrine insufficiency</span><span class="headingEndMark"> — </span>A contributory factor to the extreme weight loss often seen in patients with pancreatic cancer may be pancreatic exocrine insufficiency, which leads to maldigestion, fat malabsorption, and steatorrhea. The main clinical manifestation is weight loss. We suggest that patients who are suspected of having pancreatic exocrine insufficiency be treated empirically with oral pancreatic enzyme replacement.</p><p>Pancreatic exocrine insufficiency is a major consequence of loss of pancreatic parenchyma and/or obstruction of the main pancreatic duct. It can occur after surgery, after irradiation, or as a result of tumor compressing or obstructing the main duct [<a href="#rid92">92,93</a>]. Although there are a limited range of studies investigating the incidence of exocrine insufficiency in pancreatic cancer, the available evidence suggests that pancreatic enzyme insufficiency is common, affecting 64 to 100 percent of patients with pancreatic cancer, even those who have not had surgery [<a href="#rid94">94-97</a>]. Fat malabsorption does not become evident until lipase secretion is less than 10 percent of normal levels. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a> and  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults"</a>.)</p><p>Pancreatic enzyme insufficiency causes nonspecific symptoms such as abdominal cramping, flatulence, urgency to defecate, and weight loss. The typical characteristics of fatty stools associated with steatorrhea (loose, greasy, foul-smelling, voluminous stools that are difficult to flush) may not be evident because patients tend to limit fat ingestion. As a result, the main clinical manifestation is malnutrition and weight loss. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption", section on 'Clinical manifestations'</a>.)</p><p>Given the high incidence of pancreatic enzyme insufficiency, diagnostic testing is not necessary. Patients who are suspected of having fat malabsorption should be treated empirically with oral pancreatic enzyme replacement therapy. Adequate dosing and patient compliance are critical to the success of therapy. (See <a class="local">'Treatment'</a> below and  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults", section on 'Directed therapy based on the underlying etiology'</a>.)</p><p>However, despite this general recommendation from expert groups, including the NCCN [<a href="#rid86">86</a>] and the British Society of Gastroenterology [<a href="#rid98">98</a>], the available evidence suggests that pancreatic enzyme replacement therapy is underutilized. In a review of 129 patients with metastatic pancreatic cancer who were referred to a specialist palliative care service in Australia, over 70 percent had symptoms that could be attributed to malabsorption (abdominal pain, bloating, gaseousness, and steatorrhea), but only 21 percent were prescribed pancreatic enzyme replacement therapy [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H333622530"><span class="h4">Treatment</span><span class="headingEndMark"> — </span>Formulations of pancreatic replacement enzymes are comprised of multiple replacement enzymes, with dosing in increments of 12,000 international units. As a general rule, 30,000 international units of pancreatic lipase, swallowed during each full meal, should suffice in reducing steatorrhea and preventing weight loss. One-half of that dose should be administered with snacks. Determining the adequate amount of lipase can be confusing since the amount of lipase in commercially available pancreatic supplements is typically expressed in United States Pharmacopeia (USP) units. 30,000 international units is equivalent to approximately 90,000 USP units. (See  <a class="medical medical_review" href="/d/html/5647.html" rel="external">"Chronic pancreatitis: Management", section on 'Pancreatic enzyme replacement therapy'</a>.)</p><p>Several commercial preparations are microencapsulated  (<a class="graphic graphic_table graphicRef57416" href="/d/graphic/57416.html" rel="external">table 6</a>) and are designed to be acid-resistant, thus avoiding enzyme inactivation by gastric juice. Although data are limited, the efficacy of high-dose enteric-coated enzyme supplements was shown in two small placebo-controlled trials of patients with pancreatic insufficiency or pancreatic surgery [<a href="#rid100">100</a>] and another in advanced pancreatic cancer [<a href="#rid101">101</a>]; in both studies, use of enzyme supplements was associated with improved weight gain and decreased fat and protein malabsorption. In another small randomized trial, enteric-coated enzyme supplements resulted in higher body weight gain than did non-enteric-coated supplements following pancreaticoduodenectomy [<a href="#rid102">102</a>].</p><p>Microencapsulated formulations will only delay the release of the enzymes in the proximal small intestine and are, therefore, intended more for patients who have retained the ability to secrete gastric acid. Nonencapsulated formulations may be more successful in patients who are achlorhydric or who have dyssynchronous gastric emptying (eg, Billroth II anatomy) since there is no need to protect the enzymes from acid. (See  <a class="medical medical_review" href="/d/html/5647.html" rel="external">"Chronic pancreatitis: Management", section on 'Pancreatic enzyme replacement therapy'</a>.)</p><p>Patients should be instructed to take enzyme supplementation at the start, at the middle, and near the end of a meal. Patient compliance is a key factor in the management of pancreatic enzyme insufficiency with oral pancreatic enzymes. In addition, underdosing of enzymes, acidic intestinal pH (the enteric-coated tablets require a pH&gt;5 for the pancreatic enzymes to be released [<a href="#rid103">103</a>]), and intestinal bacterial overgrowth may also hinder the return of fat digestion to normal [<a href="#rid104">104,105</a>]. In cases of an insufficient response to enzyme supplementation, dosing and compliance should be reviewed, and consideration should be given to inhibition of gastric acid secretion.</p><p class="headingAnchor" id="H371010444"><span class="h4">Role of dietary modification</span><span class="headingEndMark"> — </span>Classically, the approach to patients with pancreatic enzyme insufficiency was to restrict fat intake (typically to &lt;20 g per day) in an attempt to reduce steatorrhea. However, this approach restricts intake of fat-soluble vitamins, which are already malabsorbed in patients with enzyme insufficiency [<a href="#rid106">106</a>]. Furthermore, the available data suggest that the half-life of enzyme activity (both endogenous and exogenously administered) within the small bowel is enhanced by the presence of fat [<a href="#rid107">107</a>]. Finally, in a dog model, both fat absorption and digestion were higher when enzyme supplements were taken with a high-fat as compared with a low-fat diet [<a href="#rid108">108</a>]. For all of these reasons, fat restriction should no longer be considered the rule in managing patients with pancreatic enzyme insufficiency. Frequent meals of a low volume and avoidance of foods that are difficult to digest (eg, legumes) are generally recommended [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H2026833577"><span class="h2">Ascites</span><span class="headingEndMark"> — </span>Ascites in patients with metastatic pancreatic cancer may be due to peritoneal metastases [<a href="#rid4">4</a>]. However, among patients with locally advanced tumors, ascites may be caused by portal vein thrombus if the tumor compresses the portal vein locally [<a href="#rid3">3</a>]. Ascites can be either transudative or exudative due to these differing causalities. (See  <a class="medical medical_review" href="/d/html/1240.html" rel="external">"Malignancy-related ascites"</a>.)</p><p>Patients with malignant ascites from pancreatic cancer can experience abdominal discomfort, nausea, vomiting, and dyspnea from the pressure of the fluid against the anterior abdominal wall and diaphragm. For most patients, median survival is short, and the focus should be on symptom control [<a href="#rid109">109</a>]. Symptom relief from intermittent paracentesis tends to be short lived, and the procedure must be repeated for symptom relief. If reaccumulation requires more than once-weekly paracentesis, placement of a long-term drainage catheter is a suitable option, although complication rates are higher with indwelling catheters [<a href="#rid109">109</a>].</p><p>Diuretics such as <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> and <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> decrease the absorption of water and sodium in the kidneys and may provide some symptomatic relief. Patients with portal hypertension due to massive liver metastases or malignant Budd-Chiari syndrome may be more likely to respond to diuretics than are patients with peritoneal carcinomatosis. Assessing the serum-to-ascites albumin gradient (SAAG) is helpful in confirming etiology and guiding treatment approaches. (See  <a class="medical medical_review" href="/d/html/1261.html" rel="external">"Evaluation of adults with ascites", section on 'Serum-to-ascites albumin gradient'</a>.)</p><p class="headingAnchor" id="H2889834742"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111947.html" rel="external">"Society guideline links: Pancreatic cancer"</a>.)</p><p class="headingAnchor" id="H15023904"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Palliative treatment designed to control the symptoms of unresectable or recurrent pancreatic cancer can provide relief of obstructive jaundice, gastric outlet obstruction, pain, and pancreatic exocrine insufficiency.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early palliative care involvement</strong> – Full assessment of symptom burden, psychological status, and social supports is required for all patients as early as possible. Early referral and initiation of palliative care services improve clinical and quality of care outcomes and may prolong survival. (See <a class="local">'Importance of palliative care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients should have pain addressed at every clinic visit. The mainstay of pain management is opioid medication. Because of the proximity of the tumor to the celiac plexus, the pain may be neuropathic, warranting consideration of adjuvant medications such as <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, or <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>. (See <a class="local">'Pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early celiac plexus neurolysis (CPN) provides better pain control, less opioid consumption, and a better quality of life as compared with waiting until after failure to obtain pain relief with strong opioids. Where local expertise is available, CPN is generally preferred over radiation therapy (RT) because relief from pain is generally faster with CPN. (See <a class="local">'Sympathetic neurolytic blocks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing biliary and gastric outlet obstruction</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palliation of jaundice in patients with unresectable pancreatic cancer is usually accomplished by the placement of an expandable metal stent. Surgical bypass is reserved for those in whom stent placement is not possible due to technical reasons and for those found to be unresectable at the time of operative exploration. (See <a class="local">'Jaundice'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopically placed expandable metal stents are preferred over palliative gastrojejunostomy for patients with symptomatic gastric outlet obstruction who are not undergoing an attempt at surgical resection. (See <a class="local">'Gastric outlet obstruction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE prophylaxis</strong> <strong>and treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The incidence of venous thromboembolism (VTE) is four- to sevenfold higher in pancreatic cancer as in other common adenocarcinomas. All patients should be educated as to the warning signs and symptoms of VTE. (See <a class="local">'Venous thromboembolism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most ambulatory patients with pancreatic cancer and no other risk factors for VTE, we do not routinely offer VTE prophylaxis, as this approach failed to improve overall survival in randomized trials. However, VTE prophylaxis is an option for select patients with high-risk features for VTE or those without high-risk features who place a high value on avoiding VTE and are informed about the risks of anticoagulation. (See <a class="local">'Prophylaxis'</a> above and  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Whom to anticoagulate'</a>.)</p><p></p><p class="bulletIndent2">For hospitalized patients with pancreatic cancer who do not have an increased bleeding risk, we recommend short-term pharmacologic thromboprophylaxis rather than no anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Hospitalized patients'</a> above and  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p></p><p class="bulletIndent2">Available choices for prophylaxis include low molecular weight (LMW) heparin, low-dose <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, or <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> at doses recommended by the manufacturer. For most patients, we suggest LMW heparin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The standard approach to <strong>treatment</strong> of a documented (symptomatic or incidentally found) VTE in a patient with pancreatic cancer is early initiation of anticoagulation. For patients with active cancer, we suggest lifelong therapy rather than a short period of anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer LMW heparin or a direct oral anticoagulant (eg, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>) over a vitamin K antagonist or <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> for most patients who will need long-term anticoagulation. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight loss and anorexia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with locally advanced or metastatic pancreatic cancer should consult with a nutritionist and/or dietician, if this service is available. (See <a class="local">'Anorexia, cachexia, and weight loss'</a> above.)</p><p></p><p class="bulletIndent2">We suggest that patients who are suspected of having fat malabsorption be treated empirically with oral pancreatic enzyme replacement therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Adequate doses of lipase should be delivered with meals and snacks. (See <a class="local">'Pancreatic exocrine insufficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ascites</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ascites in patients with metastatic pancreatic cancer may be due to peritoneal metastases or secondary to portal vein thrombus from local tumor compression. In either case, patients may benefit from intermittent paracentesis or, if the ascites reaccumulates quickly, from placement of a long-term drainage catheter. (See <a class="local">'Ascites'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Smyth EN, Bapat B, Ball DE, et al. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clin Ther 2015; 37:1301.</a></li><li><a class="nounderline abstract_t">Khorana AA, Mangu PB, Berlin J, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:2541.</a></li><li><a class="nounderline abstract_t">Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:2654.</a></li><li><a class="nounderline abstract_t">Sohal DP, Mangu PB, Khorana AA, et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:2784.</a></li><li><a class="nounderline abstract_t">Maltoni M, Scarpi E, Dall'Agata M, et al. Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. Eur J Cancer 2016; 65:61.</a></li><li><a class="nounderline abstract_t">Jang RW, Krzyzanowska MK, Zimmermann C, et al. Palliative care and the aggressiveness of end-of-life care in patients with advanced pancreatic cancer. J Natl Cancer Inst 2015; 107.</a></li><li><a class="nounderline abstract_t">Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; 2011:CD007519.</a></li><li><a class="nounderline abstract_t">Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004; 291:1092.</a></li><li><a class="nounderline abstract_t">Ischia S, Ischia A, Polati E, Finco G. Three posterior percutaneous celiac plexus block techniques. A prospective, randomized study in 61 patients with pancreatic cancer pain. Anesthesiology 1992; 76:534.</a></li><li><a class="nounderline abstract_t">Rykowski JJ, Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. Anesthesiology 2000; 92:347.</a></li><li><a class="nounderline abstract_t">Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80:290.</a></li><li><a class="nounderline abstract_t">Lou S. Endoscopic Ultrasound-guided Celiac Plexus Neurolysis to Alleviate Intractable Pain Caused by Advanced Pancreatic Cancer. Surg Laparosc Endosc Percutan Tech 2019; 29:472.</a></li><li><a class="nounderline abstract_t">Amr YM, Makharita MY. Neurolytic sympathectomy in the management of cancer pain-time effect: a prospective, randomized multicenter study. J Pain Symptom Manage 2014; 48:944.</a></li><li><a class="nounderline abstract_t">Stefaniak T, Basinski A, Vingerhoets A, et al. A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic splanchnicectomy. Eur J Surg Oncol 2005; 31:768.</a></li><li><a class="nounderline abstract_t">Süleyman Ozyalçin N, Talu GK, Camlica H, Erdine S. Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain. Eur J Pain 2004; 8:539.</a></li><li><a class="nounderline abstract_t">Chen M, Yu H, Sun S, et al. Clinical research of percutaneous bilateral splanchnic nerve lesion for pain relief in patients with pancreatic cancer under X-ray guidance. Int J Clin Exp Med 2015; 8:20092.</a></li><li><a class="nounderline abstract_t">Fields S. Retrocrural splanchnic nerve alcohol neurolysis with a CT-guided anterior transaortic approach. J Comput Assist Tomogr 1996; 20:157.</a></li><li><a class="nounderline abstract_t">Shwita AH, Amr YM, Okab MI. Comparative Study of the Effects of the Retrocrural Celiac Plexus Block Versus Splanchnic Nerve Block, C-arm Guided, for Upper Gastrointestinal Tract Tumors on Pain Relief and the Quality of Life at a Six-month Follow Up. Korean J Pain 2015; 28:22.</a></li><li><a class="nounderline abstract_t">Dong D, Zhao M, Zhang J, et al. Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial. Anesthesiology 2021; 135:686.</a></li><li><a class="nounderline abstract_t">Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993; 217:447.</a></li><li><a class="nounderline abstract_t">Fujii-Lau LL, Bamlet WR, Eldrige JS, et al. Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointest Endosc 2015; 82:46.</a></li><li><a class="nounderline abstract_t">Staats PS, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain Med 2001; 2:28.</a></li><li><a class="nounderline abstract_t">Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29:3541.</a></li><li><a class="nounderline abstract_t">Rathmell JP, Rickerson EM, Tulsky JA, Lillemoe KD. Reassessing the Role for Sympathetic Neurolysis in Patients with Pancreatic Cancer. Anesthesiology 2021; 135:573.</a></li><li><a class="nounderline abstract_t">Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80:751.</a></li><li><a class="nounderline abstract_t">Morganti AG, Trodella L, Valentini V, et al. Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas. J Palliat Care 2003; 19:258.</a></li><li><a class="nounderline abstract_t">Ceha HM, van Tienhoven G, Gouma DJ, et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000; 89:2222.</a></li><li><a class="nounderline abstract_t">Singh SM, Longmire WP Jr, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 1990; 212:132.</a></li><li><a class="nounderline abstract_t">Watanapa P, Williamson RC. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1992; 79:8.</a></li><li><a class="nounderline abstract_t">de Rooij PD, Rogatko A, Brennan MF. Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br J Surg 1991; 78:1053.</a></li><li><a class="nounderline abstract_t">Sohn TA, Lillemoe KD, Cameron JL, et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 1999; 188:658.</a></li><li><a class="nounderline abstract_t">Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006; :CD004200.</a></li><li><a class="nounderline abstract_t">Andersen JR, Sørensen SM, Kruse A, et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30:1132.</a></li><li><a class="nounderline abstract_t">Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344:1655.</a></li><li><a class="nounderline abstract_t">Speer AG, Cotton PB, Russell RC, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57.</a></li><li><a class="nounderline abstract_t">Shepherd HA, Royle G, Ross AP, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75:1166.</a></li><li><a class="nounderline abstract_t">Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007; 33:213.</a></li><li><a class="nounderline abstract_t">Levy MJ, Baron TH, Gostout CJ, et al. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin Gastroenterol Hepatol 2004; 2:273.</a></li><li><a class="nounderline abstract_t">Chen VK, Arguedas MR, Baron TH. Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis. Clin Gastroenterol Hepatol 2005; 3:1229.</a></li><li><a class="nounderline abstract_t">Dumonceau JM, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. Endoscopy 2018; 50:910.</a></li><li><a class="nounderline abstract_t">Kruse EJ. Palliation in pancreatic cancer. Surg Clin North Am 2010; 90:355.</a></li><li><a class="nounderline abstract_t">Inamdar S, Slattery E, Bhalla R, et al. Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort. JAMA Oncol 2016; 2:112.</a></li><li><a class="nounderline abstract_t">Lamarca A, Rigby C, McNamara MG, et al. Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World J Gastroenterol 2016; 22:6065.</a></li><li><a class="nounderline abstract_t">Maire F, Hammel P, Ponsot P, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol 2006; 101:735.</a></li><li><a class="nounderline abstract_t">Hüser N, Michalski CW, Schuster T, et al. Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. Br J Surg 2009; 96:711.</a></li><li><a class="nounderline abstract_t">Espat NJ, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg 1999; 188:649.</a></li><li><a class="nounderline abstract_t">Doberneck RC, Berndt GA. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg 1987; 122:827.</a></li><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Jue TL, Storm AC, et al. ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction. Gastrointest Endosc 2021; 93:309.</a></li><li><a class="nounderline abstract_t">Jeurnink SM, Steyerberg EW, van Hooft JE, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc 2010; 71:490.</a></li><li><a class="nounderline abstract_t">Barkin JS, Goldberg RI, Sfakianakis GN, Levi J. Pancreatic carcinoma is associated with delayed gastric emptying. Dig Dis Sci 1986; 31:265.</a></li><li><a class="nounderline abstract_t">Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13:748.</a></li><li><a class="nounderline abstract_t">Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom 2015; 84:22.</a></li><li><a class="nounderline abstract_t">Jacobsson L, Ottosson JO. Initial mental disorders in carcinoma of pancreas and stomach. Acta Psychiatr Scand Suppl 1971; 221:120.</a></li><li><a class="nounderline abstract_t">Fras I, Litin EM, Bartholomew LG. Mental symptoms as an aid in the early diagnosis of carcinoma of the pancreas. Gastroenterology 1968; 55:191.</a></li><li><a class="nounderline abstract_t">Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458.</a></li><li><a class="nounderline abstract_t">Larsen AC, Dabrowski T, Frøkjær JB, et al. Prevalence of venous thromboembolism at diagnosis of upper gastrointestinal cancer. Br J Surg 2014; 101:246.</a></li><li><a class="nounderline abstract_t">Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006; 42:410.</a></li><li><a class="nounderline abstract_t">Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48:1283.</a></li><li><a class="nounderline abstract_t">Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117:1334.</a></li><li><a class="nounderline abstract_t">Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119:648.</a></li><li><a class="nounderline abstract_t">Blanco ABR, Martin AJM, Alfonso PG, et al. Incidence and prediction of venous thromboembolism (VTE) in ambulatory patients (pts) with pancreas cancer receiving chemotherapy. J Clin Oncol 2012; 30S:ASCO #368.</a></li><li><a class="nounderline abstract_t">Epstein AS, Soff GA, Capanu M, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 2012; 118:3053.</a></li><li><a class="nounderline abstract_t">Søgaard KK, Farkas DK, Pedersen L, Sørensen HT. Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. Blood 2015; 126:957.</a></li><li><a class="nounderline abstract_t">Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010; 125:490.</a></li><li><a class="nounderline abstract_t">Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38:496.</a></li><li><a class="nounderline abstract_t">Vadhan-Raj S, Zhou X, Varadhachary GR, et al. Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. Blood 2013; 122:580.</a></li><li><a class="nounderline abstract_t">Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol 2015; 33:2028.</a></li><li><a class="nounderline abstract_t">Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2019; 380:711.</a></li><li><a class="nounderline abstract_t">Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720.</a></li><li><a class="nounderline abstract_t">Vadhan-Raj S, McNamara MG, Venerito M, et al. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med 2020; 9:6196.</a></li><li><a class="nounderline abstract_t">Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med 2009; 122:1077.</a></li><li><a class="nounderline abstract_t">Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146:278.</a></li><li><a class="nounderline abstract_t">Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167:1476.</a></li><li><a class="nounderline abstract_t">Själander A, Jansson JH, Bergqvist D, et al. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med 2008; 263:52.</a></li><li><a class="nounderline abstract_t">Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14.</a></li><li><a class="nounderline abstract_t">Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 2006; 22:31.</a></li><li><a class="nounderline abstract_t">Bump GM, Dandu M, Kaufman SR, et al. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. J Hosp Med 2009; 4:289.</a></li><li><a class="nounderline abstract_t">McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J 2006; 4:17.</a></li><li><a class="nounderline abstract_t">Laporte S, Liotier J, Bertoletti L, et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J Thromb Haemost 2011; 9:464.</a></li><li><a class="nounderline abstract_t">Greig MF, Rochow SB, Crilly MA, Mangoni AA. Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence? Age Ageing 2013; 42:428.</a></li><li><a class="nounderline abstract_t">Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 2014; :CD003747.</a></li><li><a class="nounderline abstract_t">Lilly CM, Liu X, Badawi O, et al. Thrombosis prophylaxis and mortality risk among critically ill adults. Chest 2014; 146:51.</a></li><li><a class="nounderline abstract_t">Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110:1723.</a></li><li><a class="nounderline abstract_t">Solari V, Jesudason EC, Turnbull JE, Yates EA. Determining the anti-coagulant-independent anti-cancer effects of heparin. Br J Cancer 2010; 103:593.</a></li><li><a class="nounderline abstract_t">Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; :CD006650.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:2189.</a></li><li><a class="nounderline abstract_t">Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.</a></li><li><a class="nounderline abstract_t">Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23:e334.</a></li><li><a class="nounderline abstract_t">Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7:760.</a></li><li><a class="nounderline abstract_t">Danai LV, Babic A, Rosenthal MH, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 2018; 558:600.</a></li><li><a class="nounderline abstract_t">Perez MM, Newcomer AD, Moertel CG, et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983; 52:346.</a></li><li><a class="nounderline abstract_t">DiMagno EP, Malagelada JR, Go VL. The relationships between pancreatic ductal obstruction and pancreatic secretion in man. Mayo Clin Proc 1979; 54:157.</a></li><li><a class="nounderline abstract_t">Matsumoto J, Traverso LW. Exocrine function following the whipple operation as assessed by stool elastase. J Gastrointest Surg 2006; 10:1225.</a></li><li><a class="nounderline abstract_t">Kato H, Nakao A, Kishimoto W, et al. 13C-labeled trioctanoin breath test for exocrine pancreatic function test in patients after pancreatoduodenectomy. Am J Gastroenterol 1993; 88:64.</a></li><li><a class="nounderline abstract_t">Sabater L, Ausania F, Bakker OJ, et al. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg 2016; 264:949.</a></li><li><a class="nounderline abstract_t">Saito T, Hirano K, Isayama H, et al. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Pancreas 2017; 46:341.</a></li><li><a class="nounderline abstract_t">Pancreatric Section, British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, et al. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005; 54 Suppl 5:v1.</a></li><li><a class="nounderline abstract_t">Landers A, Muircroft W, Brown H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. BMJ Support Palliat Care 2016; 6:75.</a></li><li><a class="nounderline abstract_t">Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastroenterol 2010; 105:2276.</a></li><li><a class="nounderline abstract_t">Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998; 42:92.</a></li><li><a class="nounderline abstract_t">Braga M, Cristallo M, De Franchis R, et al. Pancreatic enzyme replacement therapy in post-pancreatectomy patients. Int J Pancreatol 1989; 5 Suppl:37.</a></li><li><a class="nounderline abstract_t">Guarner L, Rodríguez R, Guarner F, Malagelada JR. Fate of oral enzymes in pancreatic insufficiency. Gut 1993; 34:708.</a></li><li><a class="nounderline abstract_t">Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol 2011; 26 Suppl 2:12.</a></li><li><a class="nounderline abstract_t">Domínguez-Muñoz JE, Iglesias-García J, Iglesias-Rey M, Vilariño-Insua M. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut 2006; 55:1056.</a></li><li><a class="nounderline abstract_t">Domínguez-Muñoz JE, Iglesias-García J, Vilariño-Insua M, Iglesias-Rey M. 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2007; 5:484.</a></li><li><a class="nounderline abstract_t">Holtmann G, Kelly DG, Sternby B, DiMagno EP. Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. Am J Physiol 1997; 273:G553.</a></li><li><a class="nounderline abstract_t">Suzuki A, Mizumoto A, Rerknimitr R, et al. Effect of bacterial or porcine lipase with low- or high-fat diets on nutrient absorption in pancreatic-insufficient dogs. Gastroenterology 1999; 116:431.</a></li><li><a class="nounderline abstract_t">Hicks AM, Chou J, Capanu M, et al. Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. Clin Colorectal Cancer 2016; 15:360.</a></li></ol></div><div id="topicVersionRevision">Topic 2505 Version 68.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907619" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247221" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247216" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247222" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472648" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609233" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Palliative care and the aggressiveness of end-of-life care in patients with advanced pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412903" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Celiac plexus block for pancreatic cancer pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996778" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550278" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Three posterior percutaneous celiac plexus block techniques. A prospective, randomized study in 61 patients with pancreatic cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691219" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818115" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31107855" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endoscopic Ultrasound-guided Celiac Plexus Neurolysis to Alleviate Intractable Pain Caused by Advanced Pancreatic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24798104" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neurolytic sympathectomy in the management of cancer pain-time effect: a prospective, randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15923103" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic splanchnicectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531222" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884922" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical research of percutaneous bilateral splanchnic nerve lesion for pain relief in patients with pancreatic cancer under X-ray guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8576469" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Retrocrural splanchnic nerve alcohol neurolysis with a CT-guided anterior transaortic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589943" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparative Study of the Effects of the Retrocrural Celiac Plexus Block Versus Splanchnic Nerve Block, C-arm Guided, for Upper Gastrointestinal Tract Tumors on Pain Relief and the Quality of Life at a Six-month Follow Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34398950" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683868" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800661" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of celiac neurolysis on survival in patients with pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15102315" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844506" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34499098" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Reassessing the Role for Sympathetic Neurolysis in Patients with Pancreatic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2898536" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14959596" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11147592" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1695834" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surgical palliation for pancreatic cancer. The UCLA experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1371087" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Surgical palliation for pancreatic cancer: developments during the past two decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718529" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of palliative surgical procedures in unresectable pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359359" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437477" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Palliative biliary stents for obstructing pancreatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475392" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996958" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2439854" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2466520" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157990" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15067620" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361049" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30086596" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20362791" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Palliation in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513013" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468198" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635221" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19526616" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359358" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2439057" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33168194" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20003966" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3004847" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pancreatic carcinoma is associated with delayed gastric emptying.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7884435" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pain and depression in patients with newly diagnosed pancreas cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25547421" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mood and anxiety disorders as early manifestations of medical illness: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5286323" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Initial mental disorders in carcinoma of pancreas and stomach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4385690" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mental symptoms as an aid in the early diagnosis of carcinoma of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505267" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Incidence of venous thromboembolism and its effect on survival among patients with common cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24446107" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevalence of venous thromboembolism at diagnosis of upper gastrointestinal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16321518" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22100906" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21425133" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893596" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Incidence and prediction of venous thromboembolism (VTE) in ambulatory patients (pts) with pancreas cancer receiving chemotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989534" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26089394" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097409" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Venous thromboembolism and prognosis in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31381464" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987694" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30511879" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786186" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663379" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958882" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17310052" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646601" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18088252" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669147" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16786230" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19504490" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005045" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21232002" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557678" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24804622" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24722879" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Thrombosis prophylaxis and mortality risk among critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496204" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Trousseau's syndrome: multiple definitions and multiple mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20648011" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Determining the anti-coagulant-independent anti-cancer effects of heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425959" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425959" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669224" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35772465" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19245418" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925948" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Altered exocrine function can drive adipose wasting in early pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6305473" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/431121" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The relationships between pancreatic ductal obstruction and pancreatic secretion in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114009" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Exocrine function following the whipple operation as assessed by stool elastase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093586" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : 13C-labeled trioctanoin breath test for exocrine pancreatic function test in patients after pancreatoduodenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27045859" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099252" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888770" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25164613" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20502447" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9505892" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2702249" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pancreatic enzyme replacement therapy in post-pancreatectomy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504976" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Fate of oral enzymes in pancreatic insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323992" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pancreatic exocrine insufficiency: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16766768" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17445754" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9277437" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922325" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effect of bacterial or porcine lipase with low- or high-fat diets on nutrient absorption in pancreatic-insufficient dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27262896" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
